188 related articles for article (PubMed ID: 25704541)
1. BRAF V600E mutational status in bile duct adenomas and hamartomas.
Pujals A; Bioulac-Sage P; Castain C; Charpy C; Zafrani ES; Calderaro J
Histopathology; 2015 Oct; 67(4):562-7. PubMed ID: 25704541
[TBL] [Abstract][Full Text] [Related]
2. BRAF V600E mutation in biliary proliferations associated with α
Angkathunyakul N; Rosini F; Heaton N; Foskett P; Quaglia A
Histopathology; 2017 Feb; 70(3):485-491. PubMed ID: 27627051
[TBL] [Abstract][Full Text] [Related]
3. BRAF V600E mutations in bile duct adenomas.
Pujals A; Amaddeo G; Castain C; Bioulac-Sage P; Compagnon P; Zucman-Rossi J; Azoulay D; Leroy K; Zafrani ES; Calderaro J
Hepatology; 2015 Jan; 61(1):403-5. PubMed ID: 24634053
[No Abstract] [Full Text] [Related]
4. Bile duct adenoma and von Meyenburg complex-like duct arising in hepatitis and cirrhosis: pathogenesis and histological characteristics.
Aishima S; Tanaka Y; Kubo Y; Shirabe K; Maehara Y; Oda Y
Pathol Int; 2014 Nov; 64(11):551-9. PubMed ID: 25329860
[TBL] [Abstract][Full Text] [Related]
5. Cholangiocarcinoma arising in bile duct adenoma with focal area of bile duct hamartoma.
Hasebe T; Sakamoto M; Mukai K; Kawano N; Konishi M; Ryu M; Fukamachi S; Hirohashi S
Virchows Arch; 1995; 426(2):209-13. PubMed ID: 7757293
[TBL] [Abstract][Full Text] [Related]
6. BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma.
Goeppert B; Frauenschuh L; Renner M; Roessler S; Stenzinger A; Klauschen F; Warth A; Vogel MN; Mehrabi A; Hafezi M; Boehmer K; von Deimling A; Schirmacher P; Weichert W; Capper D
Mod Pathol; 2014 Jul; 27(7):1028-34. PubMed ID: 24309328
[TBL] [Abstract][Full Text] [Related]
7. Utility of DNA flow cytometry in distinguishing between malignant and benign intrahepatic biliary lesions.
Wen KW; Rabinovitch PS; Wang D; Mattis AN; Ferrell LD; Choi WT
Virchows Arch; 2020 Oct; 477(4):527-534. PubMed ID: 32296928
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemistry can help distinguish metastatic pancreatic adenocarcinomas from bile duct adenomas and hamartomas of the liver.
Hornick JL; Lauwers GY; Odze RD
Am J Surg Pathol; 2005 Mar; 29(3):381-9. PubMed ID: 15725808
[TBL] [Abstract][Full Text] [Related]
9. Albumin expression distinguishes bile duct adenomas from metastatic adenocarcinoma.
Moy AP; Arora K; Deshpande V
Histopathology; 2016 Sep; 69(3):423-30. PubMed ID: 26841202
[TBL] [Abstract][Full Text] [Related]
10. [Cholangiocarcinomas developing on multiple bile duct hamartomas syndrome].
Droy L; Sagan C; Paineau J; Gournay J; Mosnier JF
Ann Pathol; 2009 Feb; 29(1):24-7. PubMed ID: 19233090
[TBL] [Abstract][Full Text] [Related]
11. Intrahepatic bile duct adenoma (peribiliary gland hamartoma): a case report and review of literature.
Wei J; Zhang D; Yang J; Xu C
Int J Clin Exp Pathol; 2015; 8(5):5908-13. PubMed ID: 26191317
[TBL] [Abstract][Full Text] [Related]
12. Immunostaining for polycomb group protein EZH2 and senescent marker p16INK4a may be useful to differentiate cholangiolocellular carcinoma from ductular reaction and bile duct adenoma.
Sasaki M; Matsubara T; Kakuda Y; Sato Y; Nakanuma Y
Am J Surg Pathol; 2014 Mar; 38(3):364-9. PubMed ID: 24487593
[TBL] [Abstract][Full Text] [Related]
13. An immunohistochemical profile of the so-called bile duct adenoma: clues to pathogenesis.
Hughes NR; Goodman ZD; Bhathal PS
Am J Surg Pathol; 2010 Sep; 34(9):1312-8. PubMed ID: 20679879
[TBL] [Abstract][Full Text] [Related]
14. Intrahepatic cholangiocarcinoma arising in multiple bile duct hamartomas: report of two cases and review of the literature.
Xu AM; Xian ZH; Zhang SH; Chen XF
Eur J Gastroenterol Hepatol; 2009 May; 21(5):580-4. PubMed ID: 19282767
[TBL] [Abstract][Full Text] [Related]
15. Bile duct adenoma may be a precursor lesion of small duct type intrahepatic cholangiocarcinoma.
Sasaki M; Sato Y; Nakanuma Y
Histopathology; 2021 Jan; 78(2):310-320. PubMed ID: 33405289
[TBL] [Abstract][Full Text] [Related]
16. Proliferative index facilitates distinction between benign biliary lesions and intrahepatic cholangiocarcinoma.
Tsokos CG; Krings G; Yilmaz F; Ferrell LD; Gill RM
Hum Pathol; 2016 Nov; 57():61-67. PubMed ID: 27396933
[TBL] [Abstract][Full Text] [Related]
17. Cholangiocarcinoma associated with multiple bile-duct hamartomas of the liver.
Dekker A; Ten Kate FJ; Terpstra OT
Dig Dis Sci; 1989 Jun; 34(6):952-8. PubMed ID: 2470558
[TBL] [Abstract][Full Text] [Related]
18. NRAS (Q61R), BRAF (V600E) immunohistochemistry: a concomitant tool for mutation screening in melanomas.
Uguen A; Talagas M; Costa S; Samaison L; Paule L; Alavi Z; De Braekeleer M; Le Marechal C; Marcorelles P
Diagn Pathol; 2015 Jul; 10():121. PubMed ID: 26204954
[TBL] [Abstract][Full Text] [Related]
19. Bile duct adenoma and small-sized small duct type intrahepatic cholangiocarcinoma show distinct differences in genetic alterations, expression of IMP3 and EZH2 and stromal and inflammatory components.
Sasaki M; Sato Y; Nakanuma Y
Histopathology; 2023 Aug; 83(2):298-309. PubMed ID: 37140546
[TBL] [Abstract][Full Text] [Related]
20. Enhanced B-Raf protein expression is independent of V600E mutant status in thyroid carcinomas.
Kondo T; Nakazawa T; Murata S; Kurebayashi J; Ezzat S; Asa SL; Katoh R
Hum Pathol; 2007 Dec; 38(12):1810-8. PubMed ID: 17714762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
